A Study of PLH-2301 in Subjects With Sarcopenia

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of PLH-2301 in subjects with sarcopenia. Eligible subjects aged 65 years and older will be randomized to receive placebo or one of three dose levels of PLH-2301 once daily for 12 weeks. The primary objective is to assess the effect of PLH-2301 on physical function compared with placebo.
Epistemonikos ID: a926f14876d033476e6ac6e427773734072ba2ae
First added on: Feb 06, 2026